参考文献/References:
[1]Gerber Y,Weston SA,Berardi C,et al.Contemporary trends in heart failure with reduced and preserved ejection fraction after myocardial infarction:a community study[J].Am J Epidemiol,2013,178(8):1272-1280. [2]Huang CK,Kafert-Kasting S,Thum T.Preclinical and Clinical Development of Noncoding RNA Therapeutics for Cardiovascular Disease[J].Circ Res,2020(126):663-678. [3]Bootcov MR,Bauskin AR,Valenzuela SM,et al.MIC-1,a novel macrophage inhibitory cytokine,is a divergent member of the TGF-beta superfamily[J].Proc Natl Acad Sci USA,1997,94(21):11514-11519. [4]Wollert KC,Kempf T,Wallentin L.Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease[J].Clin Chem,2017,63(1):140-151. [5]Frank D,Kuhn C,Brors B,et al.Gene expression pattern in biomechanically stretched cardiomyocytes:evidence for a stretch-specific gene program[J].Hypertension,2008,51(2):309-318. [6]Li J,Cui Y,Huang A,et al.Additional Diagnostic Value of Growth Differentiation Factor-15(GDF-15)to N-Terminal B-Type Natriuretic Peptide(NT-proBNP)in Patients with Different Stages of Heart Failure[J].Med Sci Monit,2018,18(24):4992-4999. [7]Zelniker TA,Jarolim P,Silverman MG,et al.Prognostic role of GDF-15 across the spectrum of clinical risk in patients with NSTE-ACS[J].Clin Chem Lab Med,2019,57(7):1084-1092. [8]Zeng X,Li L,Wen H,et al.Growth-differentiation factor 15 as a predictor of mortality in patients with heart failure:a meta-analysis[J].Cardiovasc Med(Hagerstown),2017,18(2):53-59. [9]Xie S,Lu L,Liu L.Growth differentiation factor-15 and the risk of cardiovascular diseases and all-cause mortality:a Meta-analysis of Prospective Studies[J].Clin Cardiol,2019,42(5):513-523. [10]Stojkovic S,Kaider A,Koller L,et al.GDF-15 is a better complimentary marker for risk stratification of arrhythmic death in non-ischaemic,dilated cardiomyopathy than soluble ST2[J].J Cell Mol Med,2018,22(4):2422-2429. [11]Hao J,Cheang I,Zhang L,et al.Growth differentiation factor-15 combined with N-terminal prohormone of brain natriuretic peptide increase 1-year prognosis prediction value for patients with acute heart failure:a prospective cohort study[J].Chin Med J(Engl),2019,132(19):2278-2285. [12]Fernandez C,Rys?覿 J,Str?觟m K,et al.Circulating protein biomarkers predict incident hypertensive heart failure independently of N-terminal pro-B-type natriuretic peptide levels[J].ESC Heart Fail,2020,7(4):1891-1899. [13]George M,Jena A,Srivatsan V,et al.GDF 15--A Novel Biomarker in the Offing for Heart Failure[J].Curr Cardiol Rev,2016,12(1):37-46. [14]Bouabdallaoui N,Claggett B,Zile MR,et al.Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction:the PARADIGM-HF trial[J].Eur J Heart Fail,2018,20(12):1701-1709. [15]Barondes SH,Castronovo V,Cooper DN,et al.Galectins:a family of animal beta-galactoside-binding lectins[J].Cell,1994(76):597-598. [16]Sharma UC,Pokharel S,van Brakel TJ,et al.Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction[J].Circulation,2004,110(19):3121-3128. [17]Gehlken C,Suthahar N,Meijers WC,et al.Galectin-3 in Heart Failure:An Update of the Last 3 Years[J].Heart Fail Clin,2018,14(1):75-92. [18]Chen A,Hou W,Zhang Y,et al.Prognostic value of serum galectin-3 in patients with heart failure:a meta-analysis[J].Int J Cardiol,2015(182):168-170. [19]Meijers WC,Januzzi JL,de Filippi C,et al.Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure:a pooled analysis of 3 clinical trials[J].Am Heart J,2014,167(6):853-860,e4. [20]Gocer H,Günday M,?譈nal M.Plasma galectin-3 as a biomarker for clinical staging of heart failure:a cross-sectional evaluation of 100 cases[J].Clin Ter,2019,170(4):e267-e271. [21]Wang N,Dang M,Zhang W,et al.Galectin-3 is associated with severe heart failure and death:A hospital-based study in Chinese patients[J].Scand J Immunol,2020,91(5):e12826. [22]Lax A,Sanchez-Mas J,Asensio-Lopez MC,et al.Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction[J].JACC Heart Fail,2015,3(1):50-58. [23]Emdin M,Aimo A,Vergaro G,et al.sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T[J].J Am Coll Cardiol,2018,72(19):2309-2320. [24]Aimo A,Januzzi JLJr,Bayes-Genis A,et al.Clinical and Prognostic Significance of sST2 in Heart Failure:JACC Review Topic of the Week[J].J Am Coll Cardiol,2019,74(17):2193-2203. [25]Aimo A,Vergaro G,Ripoli A,et al.Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure[J].JACC Heart Fail,2017,5(4):287-296. [26]Pacho C,Domingo M,Núnez R,et al.Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients[J].BMC Geriatr,2018,18(1):109. [27]Huang A,Qi X,Hou W,et al.Prognostic value of sST2 and NT-proBNP at admission in heart failure with preserved,mid-ranged and reduced ejection fraction[J].Acta Cardiol,2018,73(1):41-48. [28]Bayes-Genis A,Zamora E,de Antonio M,et al.Soluble ST2 serum concentration and renal function in heart failure[J].J Card Fail,2013,19(11):768-775. [29]Yancy CW,Jessup M,Bozkurt B,et al.2013 ACCF/AHA guideline for the management of heart failure:executive summary:a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines[J].Circulation,2013,128(16):1810-1852. [30]Thun?覬 M,Macho B,Eugen-Olsen J.suPAR:the molecular crystal ball[J].Dis Markers,2009,27(3):157-172. [31]Eugen-Olsen J,Andersen O,Linneberg A,et al.Circulating soluble urokinase plasminogen activator receptor predicts cancer,cardiovascular disease,diabetes and mortality in the general population[J].J Intern Med,2010,268(3):296-308. [32]Ishikawa H,Izumiya Y,Shibata A,et al.Soluble urokinase-type plasminogen activator receptor represents exercise tolerance and predicts adverse cardiac events in patients with heart failure[J].Heart Vessels,2020,35(5):681-688. [33]Borné Y,Persson M,Melander O,et al.Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation[J].Eur J Heart Fail,2014,16(4):377-383. [34]Koller L,Stojkovic S,Richter B,et al.Soluble Urokinase-Type Plasminogen Activator Receptor Improves Risk Prediction in Patients With Chronic?Heart?Failure[J].JACC Heart Fail,2017,5(4):268-277. [35]Thum T,Catalucci D,Bauersachs J.MicroRNAs:novel regulators in cardiac development and disease[J].Cardiovasc Res,2008,79(4):562-570. [36]Wang X,Song C,Zhou X,et al.Mitochondria Associated MicroRNA Expression Profiling of Heart Failure[J].Biomed Res Int,2017(2017):4042509. [37]Stojkovic S,Koller L,Sulzgruber P,et al.Liver-specific microRNA-122 as prognostic biomarker in patients with chronic systolic heart failure[J].Int J Cardiol,2020(303):80-85. [38]Tijsen AJ,Creemers EE,Moerland PD,et al.MiR423-5p as a circulating biomarker for heart failure[J].Circ Res,2010,106(6):1035-1039. [39]Zhao X,Wang Y,Sun X.The functions of microRNA-208 in the heart[J].Diabetes Res Clin Pract,2020(160):108004. [40]Wahlquist C,Jeong D,Rojas-Munoz A,et al.Inhibition of miR-25 improves cardiac contractility in the failing heart[J].Nature,2014,508(7497):531-535. [41]van Rooij E,Sutherland LB,Thatcher JE,et al.Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis[J].Proc Natl Acad Sci U S A,2008,105(35):13027-13032. [42]Garg A,Foinquinos A,Jung M,et al.MiRNA-181a is a novel regulator of aldosterone-mineralocorticoid receptor-mediated cardiac remodelling[J].Eur J Heart Fail,2020,22(8):1366-1377. [43]Luo B,Zeng X,Liu P,et al.Noncoding RNAs and Heart Failure[J].Adv Exp Med Biol,2020(1229):215-229. [44]Pourafkari L,Tajlil A,Nader ND.Biomarkers in diagnosing and treatment of acute heart failure[J].Biomark Med,2019,13(14):1235-1249. [45]李晓利,王耀辉,范利,等.老年患者心力衰竭生物标志物N末端B型钠尿肽前体水平检测及影响因素分析[J].中华老年心脑血管病杂志,2020,22(10):1012-1015. [46]乔香瑞,刘军辉,花蕊,卓小桢.循环单核细胞和血浆中GDF-15和NT-proBNP对慢性心力衰竭的诊断及心血管事件的预测价值[J].南方医科大学学报,2019,39(11):1273-1279. [47]郝晓萍,邬碧波,张黎明,等.尿肝型脂肪酸结合蛋白 血清胱抑素C对急性失代偿性心力衰竭患者发生急性肾损伤的预测价值[J].中国急救医学,2019,39(9):859-863.
相似文献/References:
[1]郭俊林,张立.BNP对CRT后期疗效的临床评价[J].医学信息,2018,31(01):67.[doi:10.3969/j.issn.1006-1959.2018.01.024]
GUO Jun-lin,ZHANG li.Clinical Evaluation of BNP in Treatment of Late CRT[J].Medical Information,2018,31(14):67.[doi:10.3969/j.issn.1006-1959.2018.01.024]
[2]尹晓华,刘重元,黄 琳,等.胃癌中lncRNAs的研究进展[J].医学信息,2018,31(03):10.[doi:10.3969/j.issn.1006-1959.2018.03.004]
YIN Xiao-hua,LIU Zhong-yuan,HUANG Lin,et al.Research Progress of lncRNAs in Gastric Cancer[J].Medical Information,2018,31(14):10.[doi:10.3969/j.issn.1006-1959.2018.03.004]
[3]程 林.重组人脑利钠肽用于重症急性心肌炎伴
心力衰竭患者治疗的临床研究[J].医学信息,2018,31(08):126.[doi:10.3969/j.issn.1006-1959.2018.08.042]
CHENG Lin.Clinical Study of Recombinant Human Brain Natriuretic Peptide in the Treatment of Patients with Severe Acute Myocarditis and Heart Failure[J].Medical Information,2018,31(14):126.[doi:10.3969/j.issn.1006-1959.2018.08.042]
[4]胡丽君.螺内酯联合曲美他嗪治疗慢性心力衰竭的疗效分析[J].医学信息,2018,31(08):131.[doi:10.3969/j.issn.1006-1959.2018.08.044]
HU Li-jun.Efficacy of Spironolactone Combined with Trimetazidine in the Treatment of Chronic Heart Failure[J].Medical Information,2018,31(14):131.[doi:10.3969/j.issn.1006-1959.2018.08.044]
[5]李 铎,王建华.盐酸曲美他嗪片辅助治疗对冠心病伴心力衰竭患者氧化应激、心肌功能的影响[J].医学信息,2018,31(10):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
LI Duo,WANG Jian-hua.Effect of Trimetazidine Hydrochloride Tablets Adjuvant Therapy on Oxidative Stress and Myocardial Function in Patients with Coronary Heart Disease Complicated with Heart Failure[J].Medical Information,2018,31(14):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
[6]何玲玲,程淑芬.曲美他嗪联合琥珀酸美托洛尔治疗冠心病心力衰竭疗效观察[J].医学信息,2018,31(13):142.[doi:10.3969/j.issn.1006-1959.2018.13.042]
HE Ling-ling,CHENG Shu-fen.Therapeutic Effect of Trimetazidine Combined with Metoprolol Succinate in the Treatment of Coronary Heart Disease with Heart Failure[J].Medical Information,2018,31(14):142.[doi:10.3969/j.issn.1006-1959.2018.13.042]
[7]赵 维,廖荣宏,王爱华.糖皮质激素治疗心力衰竭疗效与安全性的Meta分析[J].医学信息,2018,31(14):70.[doi:10.3969/j.issn.1006-1959.2018.14.021]
ZHAO Wei,LIAO Rong-hong,WANG Ai-hua.Meta-analysis of the Efficacy and Safety of Glucocorticoids in the Treatment of Heart Failure[J].Medical Information,2018,31(14):70.[doi:10.3969/j.issn.1006-1959.2018.14.021]
[8]施国富,吴春阳,施亚明,等.血浆脑钠肽对射血分数保留心力衰竭患者的诊断价值研究[J].医学信息,2018,31(16):47.[doi:10.3969/j.issn.1006-1959.2018.16.013]
SHI Guo-fu,WU Chun-yang,SHI Ya-ming,et al.Diagnostic Value of Plasma Brain Natriuretic Peptide in Patients with Heart Failure Preserved by Ejection Fraction[J].Medical Information,2018,31(14):47.[doi:10.3969/j.issn.1006-1959.2018.16.013]
[9]李 宁,胡硕强.心脏再同步治疗心力衰竭的文献计量分析[J].医学信息,2018,31(19):79.[doi:10.3969/j.issn.1006-1959.2018.19.024]
LI Ning,HU Shou-qiang.Bibliometric Analysis of Cardiac Resynchronization in the Treatment of Heart Failure[J].Medical Information,2018,31(14):79.[doi:10.3969/j.issn.1006-1959.2018.19.024]
[10]颜 琼,王 静,胡 聪.慢性心力衰竭患者半年内重返住院的调查分析与对策[J].医学信息,2018,31(20):173.[doi:10.3969/j.issn.1006-1959.2018.20.055]
YAN Qiong,WANG Jing,HU Cong.Investigation and Countermeasures of Patients with Chronic Heart Failure Returning to Hospital within Half a Year[J].Medical Information,2018,31(14):173.[doi:10.3969/j.issn.1006-1959.2018.20.055]